Morphotek (United States)

Recent papers from Morphotek (United States)

1. Specific loss of adipocyte CD248 improves metabolic health via reduced white adipose tissue hypoxia, fibrosis and inflammationEBioMedicine · 2019
2. A phase 1 and randomized controlled phase 2 trial of the safety and efficacy of the combination of gemcitabine and docetaxel with ontuxizumab (MORAb‐004) in metastatic soft‐tissue sarcomasCancer · 2019
3. MORAb-202, an Antibody–Drug Conjugate Utilizing Humanized Anti-human FRα Farletuzumab and the Microtubule-targeting Agent Eribulin, has Potent Antitumor ActivityMolecular Cancer Therapeutics · 2018
4. Tumor‐shed antigen CA125 blocks complement‐mediated killing via suppression of C1q‐antibody bindingEuropean Journal of Immunology · 2018
5. CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patientsCancer Biology & Therapy · 2018
6. Tumor-Shed Antigen Affects Antibody Tumor Targeting: Comparison of Two ⁸⁹Zr-Labeled Antibodies Directed against Shed or Nonshed AntigensContrast Media & Molecular Imaging · 2018
7. Implementation of Plate Imaging for Demonstration of Monoclonality in Biologics Manufacturing DevelopmentPDA Journal of Pharmaceutical Science and Technology · 2018
8. A Randomized, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Monotherapy Ontuxizumab (MORAb-004) Plus Best Supportive Care in Patients with Chemorefractory Metastatic Colorectal CancerClinical Cancer Research · 2017
9. Improved Intraoperative Detection of Ovarian Cancer by Folate Receptor Alpha Targeted Dual-Modality ImagingMolecular Pharmaceutics · 2017
10. Site-Specific Conjugation to Native and Engineered Lysines in Human Immunoglobulins by Microbial TransglutaminaseBioconjugate Chemistry · 2017
11. Application of 3D tumoroid systems to define immune and cytotoxic therapeutic responses based on tumoroid and tissue slice culture molecular signaturesOncotarget · 2017
12. Tumor antigen CA125 suppresses antibody-dependent cellular cytotoxicity (ADCC) via direct antibody binding and suppressed Fc-γ receptor engagementOncotarget · 2017
13. Cytoreductive Surgery for Metastatic Gastrointestinal Stromal Tumors Treated With Tyrosine Kinase InhibitorsAnnals of Surgery · 2017
14. Generation of therapeutic immunoconjugates via Residue-Specific Conjugation Technology (RESPECT) utilizing a native cysteine in the light chain framework of Oryctolagus cuniculusCancer Biology & Therapy · 2017
15. Rapid high-throughput cloning and stable expression of antibodies in HEK293 cellsJournal of Immunological Methods · 2016
16. Novel antibody probes for the characterization of endosialin/TEM-1Oncotarget · 2016
17. Development of 89Zr-Ontuxizumab forin vivoTEM-1/endosialin PET applicationsOncotarget · 2016
18. Isolation of Circulating Tumor Cells from Multiple Epithelial Cancers with ApoStream ® for Detecting (or Monitoring) the Expression of Folate Receptor AlphaBiomarker Insights · 2016
19. Endosialin and Associated Protein Expression in Soft Tissue Sarcomas: A Potential Target for Anti-Endosialin Therapeutic StrategiesSarcoma · 2016
20. Phase 1b safety study of farletuzumab, carboplatin and pegylated liposomal doxorubicin in patients with platinum-sensitive epithelial ovarian cancerGynecologic Oncology · 2015